Should You Buy Xeris Biopharma Holdings Inc (XERS) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
7.300
1 Day change
0.83%
52 Week Range
10.080
Analysis Updated At
2026/01/26
Xeris Biopharma Holdings Inc (XERS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive growth in revenue and promising analyst ratings, insider selling, lack of significant trading trends, and weak technical indicators suggest that it is better to hold off on investing until more favorable conditions arise.
Technical Analysis
The technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negative and expanding downward, and the RSI is neutral at 42.137. The stock is trading below the pivot level of 7.717, with key support at 7.327 and resistance at 8.106. This suggests limited immediate upside potential.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
7
Buy
4
Positive Catalysts
Revenue growth of 37.06% YoY in Q3
Analyst upgrades with increased price targets, including Oppenheimer's bullish $18 target driven by potential commercialization of XP-
Gross margin improvement to 81.57%, up 16.60% YoY.
Neutral/Negative Catalysts
Insiders are selling, with a 259.68% increase in selling activity over the last month.
Net income dropped by -103.95% YoY, and EPS fell to
Lack of recent news or event-driven catalysts.
Stock trend analysis predicts a -3.48% decline in the next month.
Financial Performance
In Q3 2025, revenue increased by 37.06% YoY to $74.38M, driven by growth in the hypercortisolism space. However, net income dropped significantly by -103.95% YoY to $621,000, and EPS fell to 0. Gross margin improved to 81.57%, indicating operational efficiency.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Barclays initiated coverage with an Overweight rating and a $9 price target, citing easing pricing headwinds and improving investor sentiment. Piper Sandler raised the price target to $8 but maintained a Neutral rating. Oppenheimer is highly bullish with an $18 price target, driven by the potential of XP-8121 and strong commercial execution.
Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 11 USD with a low forecast of 8 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 11 USD with a low forecast of 8 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.240
Low
8
Averages
11
High
18
Current: 7.240
Low
8
Averages
11
High
18
Barclays
Overweight
initiated
$9
AI Analysis
2025-12-08
Reason
Barclays
Price Target
$9
AI Analysis
2025-12-08
initiated
Overweight
Reason
Barclays initiated coverage of Xeris Biopharma with an Overweight rating and $9 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."
Piper Sandler
David Amsellem
Neutral
maintain
$6 -> $8
2025-11-07
Reason
Piper Sandler
David Amsellem
Price Target
$6 -> $8
2025-11-07
maintain
Neutral
Reason
Piper Sandler analyst David Amsellem raised the firm's price target on Xeris Biopharma to $8 from $6 and keeps a Neutral rating on the shares. The firm notes Xeris reported a Q3 net earnings per share of 0c on total revenues of $74.4M, compared to Street estimates of 1c and $74.2M, respectively. Notably, Recorlev continues to benefit from an expanding hypercortisolism space, positioning the company for sustainable cash generation, Piper adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XERS
